Sep 20, 2017
MediSieve Founder to be Key Speaker at TCT Show 2017
On September 27, 2017, George Frodsham, founder and CEO of MediSieve, is presenting at the TCT Show.
LONDON – September 20, 2017 – On September 27, 2017, George Frodsham, founder and CEO of MediSieve, is presenting at the TCT Show. The show takes place at the NEC Birmingham from 26-28 September and is a place where manufacturers, designers, business leaders, early adopters, innovators and investors can see tomorrow’s manufacturing technology today.
An expert in his field, George will be speaking about the benefits and advantages that 3D printing can provide in the world of medtech and medical device innovation.
On September 27, the TCT Magazine 2017 Awards ceremony will take place. MediSieve have been nominated for an award in the Healthcare Application category for their for potentially life-saving magnetic blood filtration device. The device filters infected cells from a patient's bloodstream and could help improve treatment of malaria.
As the device progresses to clinical trials, MediSieve’s experts are now beginning research into ways to broaden the applications of their device, using magnetic particles to target specific disease-causing components in blood. This could include treatments for sepsis and leukaemia.
The talk will focus on the importance and value of 3D printing, which George Frodsham says was “an invaluable tool for us, particularly in the early days of development of our magnetic blood filtration technology.”
He continued: “Most important was the role it played in the iterative development of early prototypes. We frequently needed to change small physical aspects of our design, going back and forth from the lab to the workshop in order to get something that worked to our satisfaction. Our rep rap 3D printer enabled us to do this easily, quickly and cheaply.”
They’ve also been able to use the printer to manufacture tools, which has saved time and money and enabled them to progress forward quickly. Regardless of these benefits, however, for MediSieve, ultimately it’s about changing lives.
As George Frodsham continued, “The ability to get prototypes rapidly made to high quality and the ability to easily make small changes continues to benefit our R&D today as we diversify our technology to be able to treat a number of different diseases.”
To learn more about these advancements, head to the talk by George Frodsham, founder and CEO of MediSieve, at the TCT show on 27 September 2017 at 13:30.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: